针对阿尔茨海默病的多重向疗法,由瓜尼尼修饰的卡利沙和循环德克斯联合组装装载有胰岛素
Qi-Yue Zhang1,2,3, Qiang Wang4, Jing-Xuan Fu1
1Key Laboratory of Molecular Biophysics, Hebei Province, Institute of Biophysics, School of Health Sciences and Biomedical Engineering, Hebei University of Technology, Tianjin 300401, P. R. China.
ACS nano
|November 5, 2024
概括
这项研究引入了一种新的阿尔茨海默氏病 (AD) 治疗方法,该疗法使用由宏环两生物输送的胰岛素. 这种方法针对代谢功能障碍,并在小鼠模型中改善认知功能,提供了一种超出粉样β去除的新治疗途径.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生物化学
- 药物输送系统 药物输送系统
背景情况:
- 粉样β (Aβ) 是阿尔茨海默病 (AD) 的关键标,但以Aβ为中心的疗法显示出有限的疗效.
- 代谢异常,如胰岛素耐药性,在阿尔茨海默病的发病过程中具有重要意义,并且仅通过向Aβ.
研究的目的:
- 通过将胰岛素与宏环两组合一起组装来研究AD的新疗法策略.
- 在AD小鼠模型中评估瓜尼尼改性卡力沙林和循环德克斯联合组装 (GCD) 输送胰岛素的疗效.
主要方法:
- 开发了GCD联合组装作为胰岛素的输送系统.
- 对5xFAD小鼠进行了GCD-胰岛素联合组合,这是阿尔茨海默病的模型.
- 评估了斑块沉积,胰岛素抵抗,神经元亡,突触损伤和认知功能的改善.
主要成果:
- 在5xFAD小鼠中,GCD-胰岛素联合组装有效降低了粉样β斑块沉积和改善了胰岛素抵抗.
- 治疗缓解了异常的神经细胞亡和突触损伤.
- 在接受治疗的小鼠中观察到认知障碍的显著改善.
结论:
- GCD-胰岛素联合组装为阿尔茨海默病提供了一个有前途的治疗方法.
- 这种策略有效地解决了代谢失调和神经退行,为传统的Aβ向方法提供了替代方案.
更多相关视频
06:17A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis
Published on: May 22, 2018
11.8K
08:27Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
Published on: July 29, 2018
11.8K
相关概念视频
Alzheimer's Disease: Treatment
165
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
165
Alzheimer's Disease: Overview
449
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
449
Parkinson's Disease: Treatment
224
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
224
